Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ENROLLING_BY_INVITATION
Clinical Phase
PHASE4
Total Enrollment
29 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-11-08
Study Completion Date
2026-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this clinical trial is to study if an investigational study drug called Dapagliflozin could prevent heart failure from getting worse in adults with Fontan circulation. The main questions it aims to answer are:
1. Does Dapagliflozin decrease Fontan pressure?
2. Does Dapagliflozin improve exercise capacity and heart failure symptoms?
Participants will have 4 study visits and 2 follow-up phone calls. The total duration of participation in the study will be up to 5 weeks from the time of screening to the completion of the final safety evaluation. Study procedures include the collection of study-related health information and blood samples, physical examination, exercise testing, total body water assessment, blood laboratory testing, health status survey, safety evaluation phone calls, and home blood pressure monitoring.
1. Does Dapagliflozin decrease Fontan pressure?
2. Does Dapagliflozin improve exercise capacity and heart failure symptoms?
Participants will have 4 study visits and 2 follow-up phone calls. The total duration of participation in the study will be up to 5 weeks from the time of screening to the completion of the final safety evaluation. Study procedures include the collection of study-related health information and blood samples, physical examination, exercise testing, total body water assessment, blood laboratory testing, health status survey, safety evaluation phone calls, and home blood pressure monitoring.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation
NCT06762964
Fontan Circulation
Single Ventricle Heart Disease
HFpEF - Heart Failure With Preserved Ejection Fraction
RECRUITING
PHASE2
Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy
NCT04575675
Hypotension
Heart Failure
COMPLETED
PHASE4
Dapagliflozin in PRESERVED Ejection Fraction Heart Failure
NCT03030235
Chronic Heart Failure With Preserved Systolic Function
COMPLETED
PHASE4
Dapagliflozin in the Treatment of Heart Failure
NCT05727423
Heart Failure
ACTIVE_NOT_RECRUITING
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure
NCT03036124
Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background:
The Fontan palliation is subject to progressive physiologic deterioration over time due to chronic elevation in central venous pressures (CVP), compromised cardiac output, and chronic lymphatic congestion and dysfunction. As a result, in adulthood Fontan patients have high rates of hospitalization of \~30% per year and nearly universally succumb to heart failure in the patients' 40s without heart transplant. Currently, there are no medical therapies of proven benefit in prolonging the lifespan of the Fontan palliation or in improving outcomes in Fontan patients.
Rationale:
Given the unusual physiologic stress established by the Fontan palliation, there is reason to believe that sodium-glucose cotransporter-2 (SGLT2) inhibitors might be uniquely beneficial in this small but growing patient population with an orphan disease process. SGLT2 inhibitors may be beneficial for the following reasons. a) Fontan patients are set up for cardiorenal syndrome. The severe end-organ congestion and increased total body water which characterizes Fontan failure are due to compromised cardiac output and chronically and uniquely elevated CVP. SGLT2 inhibitors appear to be uniquely beneficial in this setting based on findings from Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA) trial, CANagliflozin cardioVascular Assessment Study (CANVAS) and Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients. Moreover, Griffin and Rao et al recently demonstrated the benefits of empagliflozin on renal sodium handling resulting in decreases in both plasma volume (which would be anticipated to decrease CVP) and total body water (which would be expected to decrease end-organ parenchymal edema and dysfunction). Based on similar mechanisms of action and similarly beneficial effects of dapagliflozin, the investigators anticipate that benefits will be b) Fontan patients who are overweight have a worse prognosis and SGLT2 inhibitors may facilitate modest weight loss. c) Activation of the Renin-Angiotensin-Aldosterone System (RAAS) has been implicated in the progression of Fontan circulatory deterioration, although clinical trials to investigate this hypothesis have not yielded positive results. In case the RAAS hypothesis is true, SGLT2 inhibitors should decrease renin tone by increasing sodium delivery to the macula densa. d) Fontan physiology frequently deteriorates as a result of progressively worsening ventricular systolic and diastolic function. Activation of inflammatory pathways and cardiac myocyte calcium overload have been implicated in this process in non-Fontan related heart failure, and likely play a role as well in Fontan-related heart failure. Putative anti-inflammatory effects and inhibition of the sodium/hydrogen transporter mediated by SGLT2 inhibition may therefore be of benefit in preventing progressive heart failure in Fontan palliated patients.
Study design rationale:
This is a standard study design for a pilot study to investigate the use of an FDA approved drug, dapagliflozin in a new population, namely that of adult patients with a Fontan circulation. The dose and method of administration will be identical to those currently FDA approved. The Fontan circulation was selected as a study condition as it is characterized by a circulatory state that, at baseline, mimics heart failure (elevated central venous pressure, compromised cardiac output). Given this, the investigators believe the efficacy seen in the general heart failure population will be similarly enjoyed in the Fontan population. This study is designed to define more closely the physiologic changes which dapagliflozin create in the Fontan circulation, with the goal of providing data in support of a future larger study of the drug in this population with clinical endpoints.
Study objectives:
The primary objective is to determine the efficacy (as assessed by changes in peripheral venous pressure (PVP) measured by manometry) of Dapagliflozin in decreasing CVPs in Fontan patients. The secondary objective is to Investigate the impact of Dapagliflozin on CVP, total body water, exercise capacity, and patient-reported health status in Fontan patients.
Sample size:
Based on variability in PVP in Fontan patients as published by Tan et al(14) 18.4 + 5 millimeters of mercury (mmHg) with a drop of 4 mmHg is assumed to be of clinical significance, with alpha = 5% powered at 80% a total of 26 patients would be required. Allowing for \~10%, this yields a target recruitment of 29 patients.
Statistical analyses:
For the primary endpoint, the investigators will compare the change in PVP and total body water at baseline and at the end of the study period for differences using ANOVA for the primary endpoint. For the secondary endpoint, the investigators will compare change in total body water, maximum rate of oxygen your body is able to use during exercise, the minute ventilation/carbon dioxide production, oxygen pulse, and oxygen uptake efficiency slope assessed during cardiopulmonary exercise testing, patient reported health status outcome metric score as assessed by Adult Congenital Heart Disease Patient Reported Outcome (ACHD PRO) between baseline and at the end of the study period using ANOVA for the secondary endpoints.
The Fontan palliation is subject to progressive physiologic deterioration over time due to chronic elevation in central venous pressures (CVP), compromised cardiac output, and chronic lymphatic congestion and dysfunction. As a result, in adulthood Fontan patients have high rates of hospitalization of \~30% per year and nearly universally succumb to heart failure in the patients' 40s without heart transplant. Currently, there are no medical therapies of proven benefit in prolonging the lifespan of the Fontan palliation or in improving outcomes in Fontan patients.
Rationale:
Given the unusual physiologic stress established by the Fontan palliation, there is reason to believe that sodium-glucose cotransporter-2 (SGLT2) inhibitors might be uniquely beneficial in this small but growing patient population with an orphan disease process. SGLT2 inhibitors may be beneficial for the following reasons. a) Fontan patients are set up for cardiorenal syndrome. The severe end-organ congestion and increased total body water which characterizes Fontan failure are due to compromised cardiac output and chronically and uniquely elevated CVP. SGLT2 inhibitors appear to be uniquely beneficial in this setting based on findings from Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA) trial, CANagliflozin cardioVascular Assessment Study (CANVAS) and Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients. Moreover, Griffin and Rao et al recently demonstrated the benefits of empagliflozin on renal sodium handling resulting in decreases in both plasma volume (which would be anticipated to decrease CVP) and total body water (which would be expected to decrease end-organ parenchymal edema and dysfunction). Based on similar mechanisms of action and similarly beneficial effects of dapagliflozin, the investigators anticipate that benefits will be b) Fontan patients who are overweight have a worse prognosis and SGLT2 inhibitors may facilitate modest weight loss. c) Activation of the Renin-Angiotensin-Aldosterone System (RAAS) has been implicated in the progression of Fontan circulatory deterioration, although clinical trials to investigate this hypothesis have not yielded positive results. In case the RAAS hypothesis is true, SGLT2 inhibitors should decrease renin tone by increasing sodium delivery to the macula densa. d) Fontan physiology frequently deteriorates as a result of progressively worsening ventricular systolic and diastolic function. Activation of inflammatory pathways and cardiac myocyte calcium overload have been implicated in this process in non-Fontan related heart failure, and likely play a role as well in Fontan-related heart failure. Putative anti-inflammatory effects and inhibition of the sodium/hydrogen transporter mediated by SGLT2 inhibition may therefore be of benefit in preventing progressive heart failure in Fontan palliated patients.
Study design rationale:
This is a standard study design for a pilot study to investigate the use of an FDA approved drug, dapagliflozin in a new population, namely that of adult patients with a Fontan circulation. The dose and method of administration will be identical to those currently FDA approved. The Fontan circulation was selected as a study condition as it is characterized by a circulatory state that, at baseline, mimics heart failure (elevated central venous pressure, compromised cardiac output). Given this, the investigators believe the efficacy seen in the general heart failure population will be similarly enjoyed in the Fontan population. This study is designed to define more closely the physiologic changes which dapagliflozin create in the Fontan circulation, with the goal of providing data in support of a future larger study of the drug in this population with clinical endpoints.
Study objectives:
The primary objective is to determine the efficacy (as assessed by changes in peripheral venous pressure (PVP) measured by manometry) of Dapagliflozin in decreasing CVPs in Fontan patients. The secondary objective is to Investigate the impact of Dapagliflozin on CVP, total body water, exercise capacity, and patient-reported health status in Fontan patients.
Sample size:
Based on variability in PVP in Fontan patients as published by Tan et al(14) 18.4 + 5 millimeters of mercury (mmHg) with a drop of 4 mmHg is assumed to be of clinical significance, with alpha = 5% powered at 80% a total of 26 patients would be required. Allowing for \~10%, this yields a target recruitment of 29 patients.
Statistical analyses:
For the primary endpoint, the investigators will compare the change in PVP and total body water at baseline and at the end of the study period for differences using ANOVA for the primary endpoint. For the secondary endpoint, the investigators will compare change in total body water, maximum rate of oxygen your body is able to use during exercise, the minute ventilation/carbon dioxide production, oxygen pulse, and oxygen uptake efficiency slope assessed during cardiopulmonary exercise testing, patient reported health status outcome metric score as assessed by Adult Congenital Heart Disease Patient Reported Outcome (ACHD PRO) between baseline and at the end of the study period using ANOVA for the secondary endpoints.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Heart Failure
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dapagliflozin
4-week, Daily Oral Use of Dapagliflozin 10mg Tablet in Adults with Fontan Circulation
Group Type
OTHER
Dapagliflozin 10mg Tab
Intervention Type
DRUG
Participants will take one Dapagliflozin 10mg tablet once per day for 4 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dapagliflozin 10mg Tab
Participants will take one Dapagliflozin 10mg tablet once per day for 4 weeks.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
For inclusion in the study subjects should fulfil the following criteria based on local regulations:
1. Provision of informed consent prior to any study specific procedures
2. Female and/or male subjects aged ā„18 years
3. Subjects with Fontan circulation (in the opinion of the PI)
4. Subjects with clinical stability for 6 months preceding enrollment (in the opinion of the PI)
5. Subjects with no planned changes in medical therapy in the 1 months after enrollment
6. Subjects with no planned interventional procedures in the 1 months after enrollment
7. Negative pregnancy test (urine or serum) for female subjects of childbearing potential.
8. Female subjects must be 1 year post-menopausal, surgically sterile, or using an acceptable method of contraception (an acceptable method of contraception is defined as a barrier method in conjunction with a spermicide) for the duration of the study (from the time the subjects sign consent) and for 3 months after the last dose of Drug A/matching placebo to prevent pregnancy. In addition, oral contraceptives, approved contraceptive implant, long-term injectable contraception, intrauterine device, or tubal ligation are allowed. Oral contraception alone is not acceptable; additional barrier methods in conjunction with spermicide must be used.
9. Male subjects must be surgically sterile or using an acceptable method of contraception (defined as barrier methods in conjunction with spermicides) for the duration of the study (from the time the subjects sign consent) and for 3 months after the last dose of Drug A/matching placebo to prevent pregnancy in a partner.
10. Subjects who are blood donors should not donate blood during the study and for 3 months following the subject's last dose of dapagliflozin.
1. Provision of informed consent prior to any study specific procedures
2. Female and/or male subjects aged ā„18 years
3. Subjects with Fontan circulation (in the opinion of the PI)
4. Subjects with clinical stability for 6 months preceding enrollment (in the opinion of the PI)
5. Subjects with no planned changes in medical therapy in the 1 months after enrollment
6. Subjects with no planned interventional procedures in the 1 months after enrollment
7. Negative pregnancy test (urine or serum) for female subjects of childbearing potential.
8. Female subjects must be 1 year post-menopausal, surgically sterile, or using an acceptable method of contraception (an acceptable method of contraception is defined as a barrier method in conjunction with a spermicide) for the duration of the study (from the time the subjects sign consent) and for 3 months after the last dose of Drug A/matching placebo to prevent pregnancy. In addition, oral contraceptives, approved contraceptive implant, long-term injectable contraception, intrauterine device, or tubal ligation are allowed. Oral contraception alone is not acceptable; additional barrier methods in conjunction with spermicide must be used.
9. Male subjects must be surgically sterile or using an acceptable method of contraception (defined as barrier methods in conjunction with spermicides) for the duration of the study (from the time the subjects sign consent) and for 3 months after the last dose of Drug A/matching placebo to prevent pregnancy in a partner.
10. Subjects who are blood donors should not donate blood during the study and for 3 months following the subject's last dose of dapagliflozin.
Exclusion Criteria
1. Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site)
2. Previous enrollment or randomisation in the present study
3. Participation in another clinical study with an investigational product during the last 6 months
4. Pregnancy or breast feeding or desire to become pregnant or breast feed during the study period
5. Hospitalization within 6 months prior to enrollment
6. Arrhythmia requiring change in therapy within 6 months prior to enrollment
7. Interventional procedure of any kind (including cardioversion) within 6 months prior to enrollment
8. Difficulty with upper extremity IV placement in the past
9. Known obstruction anywhere within the venous circulation including at the level of the Glenn or Fontan anastomosis or within the pulmonary vasculature.
10. Symptomatic hypotension or systemic systolic blood pressure of \<95 millimeters of mercury (mmHg)
11. Estimated glomerular filtration rate of \<25ml per minute per 1.73m2 body surface area as assessed by Modification of Diet in Renal Disease (MDRD) calculation
12. Prior use of SGLT2 inhibitors with intolerable side effects
13. Type 1 diabetes
14. Inability to comply with the study protocol
15. Lack of English-proficiency
16. History of hypersensitivity to SGLT2 inhibitors
17. Severe hepatic impairment defined as a Model for End-stage Liver Disease (MELD) XI score of \>10
2. Previous enrollment or randomisation in the present study
3. Participation in another clinical study with an investigational product during the last 6 months
4. Pregnancy or breast feeding or desire to become pregnant or breast feed during the study period
5. Hospitalization within 6 months prior to enrollment
6. Arrhythmia requiring change in therapy within 6 months prior to enrollment
7. Interventional procedure of any kind (including cardioversion) within 6 months prior to enrollment
8. Difficulty with upper extremity IV placement in the past
9. Known obstruction anywhere within the venous circulation including at the level of the Glenn or Fontan anastomosis or within the pulmonary vasculature.
10. Symptomatic hypotension or systemic systolic blood pressure of \<95 millimeters of mercury (mmHg)
11. Estimated glomerular filtration rate of \<25ml per minute per 1.73m2 body surface area as assessed by Modification of Diet in Renal Disease (MDRD) calculation
12. Prior use of SGLT2 inhibitors with intolerable side effects
13. Type 1 diabetes
14. Inability to comply with the study protocol
15. Lack of English-proficiency
16. History of hypersensitivity to SGLT2 inhibitors
17. Severe hepatic impairment defined as a Model for End-stage Liver Disease (MELD) XI score of \>10
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, Los Angeles
OTHER
Sponsor Role
collaborator
Brett Boyer Foundation
UNKNOWN
Sponsor Role
collaborator
AstraZeneca
INDUSTRY
Sponsor Role
collaborator
Johns Hopkins University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ari Cedars
Role: PRINCIPAL_INVESTIGATOR
Johns Hopkins University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ronald Reagan UCLA Medical Center
Los Angeles, California, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Akintoye E, Miranda WR, Veldtman GR, Connolly HM, Egbe AC. National trends in Fontan operation and in-hospital outcomes in the USA. Heart. 2019 May;105(9):708-714. doi: 10.1136/heartjnl-2018-313680. Epub 2018 Oct 30.
Reference Type
BACKGROUND
Rychik J, Atz AM, Celermajer DS, Deal BJ, Gatzoulis MA, Gewillig MH, Hsia TY, Hsu DT, Kovacs AH, McCrindle BW, Newburger JW, Pike NA, Rodefeld M, Rosenthal DN, Schumacher KR, Marino BS, Stout K, Veldtman G, Younoszai AK, d'Udekem Y; American Heart Association Council on Cardiovascular Disease in the Young and Council on Cardiovascular and Stroke Nursing. Evaluation and Management of the Child and Adult With Fontan Circulation: A Scientific Statement From the American Heart Association. Circulation. 2019 Aug 6;140(6):e234-e284. doi: 10.1161/CIR.0000000000000696. Epub 2019 Jul 1.
Reference Type
BACKGROUND
Rychik J. Forty years of the Fontan operation: a failed strategy. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2010;13(1):96-100. doi: 10.1053/j.pcsu.2010.02.006. No abstract available.
Reference Type
BACKGROUND
McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, Bohm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukat A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjostrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.
Reference Type
BACKGROUND
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
Reference Type
BACKGROUND
Radholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D, Fulcher G, Barrett TD, Shaw W, Desai M, Matthews DR, Neal B. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program. Circulation. 2018 Jul 31;138(5):458-468. doi: 10.1161/CIRCULATIONAHA.118.034222.
Reference Type
BACKGROUND
Figtree GA, Radholm K, Barrett TD, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Matthews DR, Shaw W, Neal B. Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus. Circulation. 2019 May 28;139(22):2591-2593. doi: 10.1161/CIRCULATIONAHA.119.040057. Epub 2019 Mar 17. No abstract available.
Reference Type
BACKGROUND
Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, Suda N, Siwakoti K, Ahmad T, Jacoby D, Riello R, Bellumkonda L, Cox Z, Collins S, Jeon S, Turner JM, Wilson FP, Butler J, Inzucchi SE, Testani JM. Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects. Circulation. 2020 Sep 15;142(11):1028-1039. doi: 10.1161/CIRCULATIONAHA.120.045691. Epub 2020 May 15.
Reference Type
BACKGROUND
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.
Reference Type
BACKGROUND
Packer M, Anker SD, Butler J, Filippatos G, Zannad F. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action. JAMA Cardiol. 2017 Sep 1;2(9):1025-1029. doi: 10.1001/jamacardio.2017.2275.
Reference Type
BACKGROUND
Koyani CN, Plastira I, Sourij H, Hallstrom S, Schmidt A, Rainer PP, Bugger H, Frank S, Malle E, von Lewinski D. Empagliflozin protects heart from inflammation and energy depletion via AMPK activation. Pharmacol Res. 2020 Aug;158:104870. doi: 10.1016/j.phrs.2020.104870. Epub 2020 May 17.
Reference Type
BACKGROUND
Packer M. Interplay of adenosine monophosphate-activated protein kinase/sirtuin-1 activation and sodium influx inhibition mediates the renal benefits of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: A novel conceptual framework. Diabetes Obes Metab. 2020 May;22(5):734-742. doi: 10.1111/dom.13961. Epub 2020 Feb 20.
Reference Type
BACKGROUND
Cedars AM, Ko JM, John AS, Vittengl J, Stefanescu-Schmidt AC, Jarrett RB, Kutty S, Spertus JA. Development of a Novel Adult Congenital Heart Disease-Specific Patient-Reported Outcome Metric. J Am Heart Assoc. 2020 Jun 2;9(11):e015730. doi: 10.1161/JAHA.119.015730. Epub 2020 May 16.
Reference Type
BACKGROUND
Tan W, Small A, Gallotti R, Moore J, Aboulhosn J. Peripheral venous pressure accurately predicts central venous pressure in the adult Fontan circulation. Int J Cardiol. 2021 Mar 1;326:77-80. doi: 10.1016/j.ijcard.2020.11.007. Epub 2020 Nov 13.
Reference Type
BACKGROUND
Kushner RF, Schoeller DA. Estimation of total body water by bioelectrical impedance analysis. Am J Clin Nutr. 1986 Sep;44(3):417-24. doi: 10.1093/ajcn/44.3.417.
Reference Type
BACKGROUND
Bedogni G, Malavolti M, Severi S, Poli M, Mussi C, Fantuzzi AL, Battistini N. Accuracy of an eight-point tactile-electrode impedance method in the assessment of total body water. Eur J Clin Nutr. 2002 Nov;56(11):1143-8. doi: 10.1038/sj.ejcn.1601466.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ESR-21-21445
Identifier Type: OTHER
Identifier Source: secondary_id
IRB00254477
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Dapa Acute Heart Failure Study
NCT05759000
RECRUITING
Stratified Treatment to Ameliorate Diastolic Left Ventricular Stiffness in Heart Failure With Preserved Ejection Fraction
NCT04475042
UNKNOWN
PHASE2
Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure
NCT04956809
COMPLETED
PHASE2
Dapagliflozin in Systemic Right Ventricle (DAPA-SERVE)
NCT05717257
UNKNOWN
PHASE4
Dapagliflozin And Pulmonary Artery Hemodynamics in Heart Failure With Reduced Ejection Fraction Patients With CardioMEMSĀ®
NCT04570865
UNKNOWN
PHASE4
DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction
NCT05764057
RECRUITING
PHASE3
Effects of Dapagliflozin on Cardiorespiratory Parameters in Heart Failure
NCT05770167
UNKNOWN
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652
RECRUITING
PHASE3
Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.
NCT03619213
COMPLETED
PHASE3
Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List
NCT04782245
WITHDRAWN
PHASE2
Cardiometabolic Effects of Dapagliflozin in Heart Failure With Reduced or Mildly Reduced Ejection Fraction
NCT05420285
UNKNOWN
PHASE2
Effect of Dapagliflozin on VT in Patients With Heart Failure.
NCT05550441
UNKNOWN
PHASE4
A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure
NCT04157751
COMPLETED
PHASE3
Real-world Dapagliflozin Experience in Patients With Heart Failure in United Kingdom.
NCT05188144
COMPLETED
Efficacy and Safety of Dapagliflozin in Acute Heart Failure
NCT04298229
COMPLETED
PHASE3
Effect of Dapagliflozin on Myocardial and Renal Function Following Aortic Valve Stenosis Intervention
NCT05241431
UNKNOWN
PHASE2/PHASE3
SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF
NCT05852704
RECRUITING
PHASE3
Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure
NCT02653482
COMPLETED
PHASE4
Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.
NCT04564742
COMPLETED
PHASE3
Dapagliflozin on Volume Vascular Outcomes.
NCT04869124
COMPLETED
PHASE4
Effects of Acute and Chronic Empagliflozin Heart Failure
NCT05553938
RECRUITING
PHASE1
Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List
NCT06868797
RECRUITING
NA
DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction
NCT03877224
COMPLETED
PHASE3
Dapagliflozin With or Without Spironolactone for HFpEF
NCT05676684
COMPLETED
PHASE2/PHASE3
Short-term Effects of Dapagliflozin on Peak VO2 in HFrEF
NCT04197635
COMPLETED
PHASE4